Editas Medicine (EDIT) Return on Capital Employed (2016 - 2025)
Editas Medicine (EDIT) posted quarterly Return on Capital Employed of 137.71% for Q3 2025, down 5720.0% year-over-year from 2.45% in Q3 2024, and up 1.76% quarter-over-quarter from 140.18% in Q2 2025.
Editas Medicine (EDIT) Return on Capital Employed (2016 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Return on Capital Employed for 10 consecutive years, with 137.71% the latest figure, recorded in Q3 2025.
- In Q3 2025, Return on Capital Employed fell 5720.0% year-over-year to 137.71%; the TTM figure through Sep 2025 stood at 137.71% (down 5720.0% YoY), while the FY2024 annual figure was 73.19%, down 3505.0% from the prior year.
- Return on Capital Employed rose to 137.71% in Q3 2025 per EDIT's latest filing, from 140.18% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 23.69% in Q1 2021 and bottomed at 140.18% in Q2 2025.
- Historically, Return on Capital Employed has averaged 59.13% across 5 years, with a median of 45.93% in 2024.
- Annual changes were most pronounced in 2021 — Return on Capital Employed soared 1361 bps — and 2025, when it tumbled 7721 bps.
- Editas Medicine's Return on Capital Employed stood at 29.7% in 2021, then tumbled by 64 bps to 48.85% in 2022, then advanced by 21 bps to 38.57% in 2023, then plunged by 153 bps to 97.59% in 2024, then tumbled by 41 bps to 137.71% in 2025.
- Business Quant data shows EDIT's Return on Capital Employed at 137.71% in Q3 2025, 140.18% in Q2 2025, and 113.43% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -137.71% |
| Jun 30, 2025 | -140.18% |
| Mar 31, 2025 | -113.43% |
| Dec 31, 2024 | -97.59% |
| Sep 30, 2024 | -80.51% |
| Jun 30, 2024 | -62.97% |
| Mar 31, 2024 | -45.93% |
| Dec 31, 2023 | -38.57% |
| Sep 30, 2023 | -44.90% |
| Jun 30, 2023 | -48.16% |
| Mar 31, 2023 | -52.35% |
| Dec 31, 2022 | -48.85% |
| Sep 30, 2022 | -39.74% |
| Jun 30, 2022 | -32.86% |
| Mar 31, 2022 | -30.47% |
| Dec 31, 2021 | -29.70% |
| Sep 30, 2021 | -31.71% |
| Jun 30, 2021 | -24.10% |
| Mar 31, 2021 | -23.69% |
| Dec 31, 2020 | -25.60% |